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ABSTRACT 
 
Objectives: Obesity has been proposed as a risk factor for refractory rheumatoid 
arthritis (RA). We evaluated the impact of obesity on achieving clinical and imaging 
definitions of low disease activity. 
Methods: This study evaluated 470 patients with RA from GO-BEFORE and GO-
FORWARD randomized clinical trials. Included patients had blinded clinical disease 
activity measures and magnetic resonance imaging (MRI) at baseline, 24, and 52 weeks. 
Synovitis, osteitis, and total inflammation scores were determined using the RA MRI 
scoring system. Multivariable logistic regression analyses compared odds of achieving 
Disease Activity Score [DAS28(CRP)] remission, low component measures, or low MRI 
inflammation measures at 24 weeks in obese versus non-obese patients. 
Results: At 24 weeks, obese patients were significantly less likely to achieve DAS28(CRP) 
remission [OR (95% CI): 0.47 (0.24-0.92), p=0.03]. In contrast, obese patients had similar 
odds of achieving low synovitis [OR 0.94 (0.51-1.72), p=0.84] and inflammation scores 
[OR 1.16 (0.61-2.22), p=0.64] and greater odds of achieving low osteitis scores [OR(95% 
CI) 2.06(1.10-3.84), p=0.02] versus normal weight patients. 
Conclusions: Obese patients with RA have lower rates of DAS28 remission but similar 
rates of low MRI activity compared to non-obese patients, suggesting that obesity and 
its associated comorbidities can bias clinical disease activity measures.   
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INTRODUCTION 
Obesity is one of the most common comorbid conditions among patients with 
rheumatoid arthritis (RA). Numerous studies have suggested that patients with obesity 
have a poorer response to treatment and lower likelihood of achieving RA disease 
remission.[1 ?6] While some have concluded that obesity is associated with more 
refractory RA, an alternative explanation is that obesity and its related symptoms and 
comorbidities directly influence and bias specific components of disease activity 
measures.[7] 
 
Magnetic resonance imaging (MRI) can be used to assess both damage and 
inflammatory activity in RA. MRI measured synovitis and osteitis (bone edema) are 
sensitive to change and have been used as outcome measures in clinical trials. These 
measures are also predictive of progressive joint damage independent of clinical disease 
activity.[8 ?10] Recently, thresholds for low MRI activity have been defined and validated 
using RA magnetic resonance imaging scores (RAMRIS). These thresholds identify 
patients unlikely to have structural progression, even if definitions of clinical remission 
are not met.[10] 
 
The objective of this study was to compare the impact of obesity on attaining different 
clinical and imaging definitions of low activity and remission. We hypothesized that 
obese patients would be less likely to attain clinical remission but equally likely to meet 
MRI imaging definitions of low activity versus non-obese patients.  
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METHODS 
The study population comes from secondary analysis of the GO-BEFORE 
(Clinicaltrials.gov identifier NCT00361335) and GO-FORWARD (NCT00264550) 
randomized, multicenter, double-blind, placebo-controlled trials which evaluated the 
efficacy of tumor necrosis factor alpha (TNFa) antagonist golimumab for the treatment 
of RA. Both studies compared golimumab in combination with methotrexate to 
methotrexate or golimumab monotherapy. GO-BEFORE studied methotrexate naïve 
patients and GO-FORWARD studied patients with inadequate methotrexate response. 
Detailed methods and results of both studies have previously been published.[11,12] 
The trials were conducted according to the Declaration of Helsinki. The secondary 
analysis of de-identified trial data was considered exempt by the Internal Review Board 
at the University of Pennsylvania. 
 
This analysis includes the subset of patients in both studies who had MRIs scored for 
synovitis, osteitis, and/or bone erosion at baseline and during follow up. Patients A?18 
years old who met American College of Rheumatology 1987 criteria for RA and had 
active disease were recruited into the MRI sub-study at participating sites. Data 
collection at each 4-week visit through 52 weeks included blinded assessments of 
Disease Activity Score in 28 joints [DAS28(CRP)] and Health Assessment Questionnaire 
(HAQ). MRI was performed at baseline, week 24, and week 52. Body mass index at 
baseline was calculated as weight in kilograms divided by height in meters squared, and 
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categorized as BMI <20 (underweight), BMI 20-<25 (normal weight), BMI 25-<30 
(overweight), and BMI A?30 (obese).  
 
MRIs of the dominant wrist and 2nd-5th metacarpophalangeal (MCP) joints were 
obtained using a 1.5T MRI with contrast enhancement as previously described and 
scored by two independent blinded readers using the RAMRIS scoring system.[9] Low 
synovitis and low osteitis scores were defined as A?3 based on recently defined 
thresholds.[10] Inflammation scores were calculated by adding the synovitis score to 
twice the osteitis score as previously described, with a low score defined as A?9.[10] 
 
Clinical remission was defined as a DAS28(CRP) score <2.6. Thresholds for a low swollen 
joint count, tender joint count, patient global score, and CRP in mg/dL were all defined 
as A?1 and low HAQ as A?0.5 as defined in the 2011 ACR/EULAR Boolean definitions of 
remission.[13]  
 
Data was analyzed with STATA 13.1 software (StataCorp, LP, College Station, TX). 
Differences in demographics, disease activity, and MRI measures at baseline across BMI 
categories were evaluated with Chi-square, ANOVA, and Kruskall Wallis tests. In the 
primary analysis, multivariable logistic regression models evaluated the association 
between BMI category (normal BMI as the reference) and each of the 24-week clinical 
disease activity or imaging outcomes, adjusting for age, sex, race, anti-cyclic citrullinated 
peptide (CCP) antibody status, study, and treatment assignment. The probability of 
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reaching low activity thresholds was determined from these models for each BMI 
category at the means of all covariates and displayed graphically. Secondary analysis 
evaluated the same outcomes at 52 weeks. 
 
RESULTS 
Baseline characteristics of the 470 patients in the cohort are shown in Table 1. 
Overweight and obese patients were older and more often white. Overweight and 
obese patients had higher tender joint counts and worse HAQ scores at baseline, 
although DAS28(CRP) scores were similar across BMI categories. As has been previously 
published from this cohort, overweight and obese subjects had substantially lower 
osteitis (bone edema) scores and fewer erosions at baseline (Table 1).[14] 
 
At 24 weeks, DAS28(CRP) remission was present in 28% of underweight, 28% of normal 
weight, 27% of overweight, but only 17% of obese patients. After adjustment, obese 
patients were less likely to achieve DAS28(CRP) remission [OR (95% CI): 0.47 (0.24-0.92), 
p=0.03] or a low HAQ [OR: 0.49 (0.28-0.89), p=0.02] compared to normal weight 
patients (Figure 1) (Supplemental Table 1). Results using SDAI, CDAI, or Boolean  
remission were similar although not statistically significant (Supplemental Figure 1). 
Obese patients were also less likely to have a favorable patient global score A?1 [OR: 0.47 
(0.24-0.92), p=0.03] and less likely to have a CRP A?1 mg/dL [OR: 0.44 (0.23-0.84), p=0.01] 
at 24 weeks. Results were similar with adjustment for baseline DAS28(CRP) (not shown).  
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In contrast, low synovitis scores A?3 and low inflammation scores A?9 on MRI occurred at 
similar rates across BMI groups, while low osteitis (bone edema) scores were more 
common in obese patients (69% of obese versus 50% of normal weight patients, 
p=0.02). In multivariable models, obese patients were not less likely to have low 
synovitis [OR: 0.94 (0.51-1.72), p=0.84] or low inflammation scores [OR: 1.02 (0.53-
1.96), p=0.95] at 24 weeks versus normal weight patients (Figure 2) (Supplemental 
Table 2). Obese patients were more likely to achieve a low osteitis score compared to 
normal weight patients [OR: 2.06 (1.10-3.84), p=0.02]. The odds of a low osteitis score 
was similar across BMI categories after adjusting for baseline osteitis (obese versus 
normal weight OR: 1.01 (0.40-2.51), p=0.99). 
 
Analyses at 52 weeks were similar except that obese patients were significantly less 
likely to have a low tender joint count versus normal weight patients [OR: 0.47 (0.27-
0.82), p=0.01] and differences in achieving low HAQ were not significant (Supplemental 
Table 2). 
 
DISCUSSION 
Obesity was associated with a lower likelihood of achieving DAS28 remission among 
patients with RA enrolled in these clinical trials. In contrast, these same obese patients 
achieved low MRI activity at a similar rate compared to non-obese patients. These 
results suggest that obesity is not associated with more severe or refractory RA, but 
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rather that obesity may bias clinical disease activity measures and thereby reduce the 
likelihood of achieving remission based on clinical assessments.  
 
Patients with obesity were less likely to have low DAS28 scores at 24 and 52 weeks. 
Obese patients were also less likely to achieve a low patient global score, tender joint 
count, CRP level, and HAQ. These results support previous studies demonstrating that 
RA patients with obesity have worse subjective disease activity measures at baseline 
and poorer response of these subjective measures to treatment.[3,4,15,16] 
Inflammatory markers such as CRP, although considered more objective, may also be 
elevated in patients with obesity independent of RA disease activity.[17]  
 
In contrast, obese patients had similar rates of achieving a low MRI synovitis or total 
inflammation score and higher rates of achieving a low osteitis score at 24 and 52 weeks 
(similar rates when controlling for baseline osteitis). These observations are supported 
by previous studies showing that obesity is associated with a lower risk of radiographic 
and MRI joint damage progression.[14,18,19] This study provides new evidence that 
obesity is not associated with more severe or refractory disease by showing that obese 
patients achieve similar rates of low MRI disease activity despite apparent differences in 
clinical responses.  
 
This study utilizes clinical trial data that includes rigorous assessment of clinical disease 
activity measures and blinded MRI scoring at regular intervals.  ?ŐŽůĚƐƚĂŶĚĂƌĚ ?
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assessment of disease activity does not exist and MRI may not capture all aspects of RA 
disease activity. MRI does, however, provide an objective measure of inflammatory joint 
disease, a key and defining feature of RA. While very low levels of synovitis or osteitis 
may be common and nonspecific,[20] our use of validated cutoff scores that identify an 
informative degree of inflammatory disease is an advance over previous literature. 
Residual confounding by unmeasured factors is also possible in this observational study, 
although adjustment for baseline demographics, race, CCP antibody positivity, and 
baseline disease activity did not substantially impact the results.  
 
In conclusion, although obese patients with RA are less likely to achieve DAS28 
remission, they have similar rates of achieving low MRI activity. This study addresses an 
ongoing controversy about the impact of obesity on RA disease activity and suggests 
that obesity is not associated with more refractory RA. These results highlight the critical 
role of the clinician, whose challenge is to recognize the importance and limitations of 
disease activity measures and to consider the impact of comorbidities on disease 
activity scores and symptoms. 
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Table 1: Baseline characteristics of the study population by BMI group 
 BMI <20 
N = 51 
BMI 20-<25 
N = 164 
BMI 25-<30 
N = 152 
BMI A?30 
N = 103 
p-value 
Female 43 (84%) 136 (83%) 126 (83%) 87 (84%) 0.98 
Age, years 44 ± 14 47 ± 12 51 ± 11 52 ± 11 <0.001 
Race      
  White 15 (29%) 92 (56%) 106 (70%) 87 (84%) <0.001 
  Black 0 (0%) 0 (0%) 1 (1%) 1 (1%) 0.61 
  Asian 35 (69%) 61 (37%) 25 (16%) 7 (7%) <0.001 
  Other 1 (2%) 11 (7%) 20 (13%) 8 (8%) 0.05 
GO-BEFORE 26 (51%) 94 (57%) 89 (59%) 61 (59%) 0.78 
GO-FORWARD 25 (49%) 70 (43%) 63 (41%) 42 (41%) 0.78 
CCP positive 39 (76%) 136 (83%) 121 (80%) 75 (73%) 0.25 
DAS28(CRP) 5.5 ± 1.2 5.3 ± 1.1 5.6 ± 1.1 5.5 ± 1.0 0.06 
Swollen joint count 8.9 ± 6.0 8.7 ± 5.1 9.9 ± 5.8 9.7 ± 5.8 0.19 
Tender joint count 12.2 ± 7.4 11.5 ± 6.9 14.4 ± 7.5 13.8 ± 7.0 0.002 
Patient global 6.3 ± 2.4 5.7 ± 2.4 6.0 ± 2.4 6.0 ± 2.2 0.41 
HAQ 1.3 ± 0.7 1.3 ± 0.7 1.6 ± 0.7 1.7 ± 0.7 <0.001 
CRP, mg/dL 1.2 [0.4-3.6] 1.0 [0.3-2.4] 0.9 [0.4-2.3] 0.9 [0.4-2.0] 0.59 
RAMRIS scores at 
baseline 
     
  Synovitis 7.9 [4.5-13.5] 8.0 [4.3-12.0] 9.0 [5.0-12.5] 7.5 [4.0-10.8] 0.07 
  Osteitis 8.0 [1.0-19.5] 8.0 [1.5-18.4] 4.5 [1.4-10.1] 3.0 [0.5-9.0] <0.001 
  Inflammation 26.2 [10.1-
46.6] 
28.8 [8.6-
50.2] 
21.0 [11.0-
32.8] 
14.5 [7.4-
30.0] 
0.003 
  Bone erosion 14.5 [8.7-
37.0] 
16.4 [9.0-
40.0] 
14.0 [9.5-
22.5] 
13.5 [8.3-
20.0] 
0.02 
Mean ± SD compared with ANOVA, median [IQR] compared with Kruskall Wallis, proportions compared 
with Chi-square. 
BMI: body mass index in kg/m2. DAS28(CRP): disease activity score using 28 joints and CRP. CRP: C-
reactive protein. RAMRIS: rheumatoid arthritis magnetic resonance imaging scores 
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Figure 1: Rates of low disease activity measures at 24 weeks among different BMI 
groups. Predicted probabilities were obtained from multivariable logistic regression 
models at the means of age, sex, race, cyclic citrullinated peptide antibody status, study, 
treatment assignment.  
* p <0.05; BMI = body mass index; DAS28 = disease activity score in 28 joints using CRP; 
SJC = swollen joint count; TJC = tender joint count; PTGL = patient global VAS score; CRP 
= C-reactive protein; HAQ = health assessment questionnaire 
 
Figure 2: Rates of low clinical disease activity or low MRI scores at 24 weeks among 
different BMI groups. Predicted probabilities were obtained from multivariable logistic 
regression models at the means of age, sex, race, cyclic citrullinated peptide antibody 
status, study, treatment assignment.  
* p <0.05; BMI = body mass index; DAS28 = disease activity score in 28 joints using C-
reactive protein 
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